Research graph
References from Advances in multiple myeloma therapy during two past decades. Local targets link to admitted publications; unresolved targets remain external evidence.
Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group
10.1182/blood-2007-03-081018 · 2008 · External reference
10.1182/blood-2007-10-116129
10.1182/blood-2007-10-116129 · External reference
10.1056/nejmoa030288
10.1056/nejmoa030288 · External reference
10.1056/nejmoa043445
10.1056/nejmoa043445 · External reference
10.1182/blood-2002-06-1768
10.1182/blood-2002-06-1768 · External reference
Bortezomib in the front-line treatment of multiple myeloma
10.1586/14737140.8.7.1053 · 2008 · External reference
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
10.1200/jco.2005.03.2383 · 2006 · External reference
10.1182/blood-2006-04-019778
10.1182/blood-2006-04-019778 · External reference
VISTA trial investigators: bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
10.1056/nejmoa0801479 · 2008 · External reference
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study
10.1200/jco.2009.22.2232 · 2009 · External reference
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
10.1200/jco.2009.26.0638 · 2010 · External reference
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan–prednisone versus melphalan–prednisone
10.1182/blood-2010-03-275800 · 2010 · External reference
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
10.1200/jco.2011.39.6820 · 2012 · External reference
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
10.3324/haematol.2013.087585 · 2014 · External reference
Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract 92]
10.1182/blood.v112.11.92.92 · 2008 · External reference
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
10.1182/blood-2011-11-395749 · 2012 · External reference
10.1056/nejmoa070594
10.1056/nejmoa070594 · External reference
Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
10.1056/nejmoa070596 · 2007 · External reference
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
10.1016/s1470-2045(09)70284-0 · 2010 · External reference
10.1056/nejmoa1112704
10.1056/nejmoa1112704 · External reference
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure
10.1200/jco.2008.18.8573 · 2009 · External reference
Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX maintenance randomisation [abstract 656]
10.1182/blood.v112.11.656.656 · 2008 · External reference
10.1056/nejmoa1114138
10.1056/nejmoa1114138 · External reference
10.1056/nejmoa1114083
10.1056/nejmoa1114083 · External reference
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial
10.1182/blood.v122.21.406.406 · 2013 · External reference
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
10.1016/s1470-2045(10)70187-x · 2010 · External reference
10.1016/j.leukres.2013.03.006
10.1016/j.leukres.2013.03.006 · External reference
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
2013 · External reference
